BACKGROUND: The discovery of new, effective non-anthracycline-based reinduction regimens for children with recurrent acute myeloid leukemia (AML) is critical. In this phase 1/2 study, the tolerability and overall response rate of clofarabine in combination with cytarabine was investigated in children with recurrent/refractory AML. METHODS: AAML0523 enrolled 49 children with AML in first recurrence or who were refractory to induction therapy. The study consisted of a dose-finding phase (9 patients) and an efficacy phase (40 patients). Two children received clofarabine at a dose of 40 mg/m(2)/day and 47 children at a dose of 52 mg/m(2)/day. RESULTS: Toxicities typical for intensive chemotherapy regimens were observed at all doses of clofarabine. The recommended pediatric phase 2 dose of clofarabine in combination with cytarabine was 52 mg/m(2)/day for 5 days. Of 48 evaluable patients, the overall response rate (complete remission plus complete remission with partial platelet recovery) was 48%. Four patients met conventional criteria for complete remission with incomplete count recovery. Twenty-one of 23 responders subsequently underwent hematopoietic stem cell transplantation. The overall survival rate at 3 years was 46% for responders compared with 16% for nonresponders (P < .001). Patients found to have no minimal residual disease at the end of the first cycle by flow cytometric analysis had superior overall survival after 1 year (100% vs 38%; P = .01). CONCLUSIONS: The combination of clofarabine and cytarabine yielded an acceptable response rate without excess toxicity in children with recurrent AML. The nearly 50% survival rate reported in responders is highly encouraging in these high-risk patients and suggests that this combination is an effective bridge to hematopoietic stem cell transplantation.
BACKGROUND: The discovery of new, effective non-anthracycline-based reinduction regimens for children with recurrent acute myeloid leukemia (AML) is critical. In this phase 1/2 study, the tolerability and overall response rate of clofarabine in combination with cytarabine was investigated in children with recurrent/refractory AML. METHODS: AAML0523 enrolled 49 children with AML in first recurrence or who were refractory to induction therapy. The study consisted of a dose-finding phase (9 patients) and an efficacy phase (40 patients). Two children received clofarabine at a dose of 40 mg/m(2)/day and 47 children at a dose of 52 mg/m(2)/day. RESULTS:Toxicities typical for intensive chemotherapy regimens were observed at all doses of clofarabine. The recommended pediatric phase 2 dose of clofarabine in combination with cytarabine was 52 mg/m(2)/day for 5 days. Of 48 evaluable patients, the overall response rate (complete remission plus complete remission with partial platelet recovery) was 48%. Four patients met conventional criteria for complete remission with incomplete count recovery. Twenty-one of 23 responders subsequently underwent hematopoietic stem cell transplantation. The overall survival rate at 3 years was 46% for responders compared with 16% for nonresponders (P < .001). Patients found to have no minimal residual disease at the end of the first cycle by flow cytometric analysis had superior overall survival after 1 year (100% vs 38%; P = .01). CONCLUSIONS: The combination of clofarabine and cytarabine yielded an acceptable response rate without excess toxicity in children with recurrent AML. The nearly 50% survival rate reported in responders is highly encouraging in these high-risk patients and suggests that this combination is an effective bridge to hematopoietic stem cell transplantation.
Authors: Sima Jeha; Paul S Gaynon; Bassem I Razzouk; Janet Franklin; Richard Kadota; Violet Shen; Lori Luchtman-Jones; Michael Rytting; Lisa R Bomgaars; Susan Rheingold; Kim Ritchey; Edythe Albano; Robert J Arceci; Stewart Goldman; Timothy Griffin; Arnold Altman; Bruce Gordon; Laurel Steinherz; Steven Weitman; Peter Steinherz Journal: J Clin Oncol Date: 2006-04-20 Impact factor: 44.544
Authors: W B Parker; S C Shaddix; L M Rose; D S Shewach; L W Hertel; J A Secrist; J A Montgomery; L L Bennett Journal: Mol Pharmacol Date: 1999-03 Impact factor: 4.436
Authors: Stefan Faderl; Varsha Gandhi; Susan O'Brien; Peter Bonate; Jorge Cortes; Elihu Estey; Miloslav Beran; William Wierda; Guillermo Garcia-Manero; Alessandra Ferrajoli; Zeev Estrov; Francis J Giles; Min Du; Monica Kwari; Michael Keating; William Plunkett; Hagop Kantarjian Journal: Blood Date: 2004-10-14 Impact factor: 22.113
Authors: Etan Orgel; Laura Zung; Lingyun Ji; Jerry Finklestein; James Feusner; David R Freyer Journal: Pediatr Blood Cancer Date: 2013-02-25 Impact factor: 3.167
Authors: Yogesh T Patel; Megan O Jacus; Nidal Boulos; Jason D Dapper; Abigail D Davis; Pradeep K Vuppala; Burgess B Freeman; Kumarasamypet M Mohankumar; Stacy L Throm; Richard J Gilbertson; Clinton F Stewart Journal: Cancer Chemother Pharmacol Date: 2015-02-28 Impact factor: 3.333
Authors: Todd M Cooper; Michael J Absalon; Todd A Alonzo; Robert B Gerbing; Kasey J Leger; Betsy A Hirsch; Jessica Pollard; Bassem I Razzouk; Richard Aplenc; E Anders Kolb Journal: J Clin Oncol Date: 2020-05-13 Impact factor: 44.544
Authors: Barbara Spitzer; Miguel-Angel Perales; Nancy A Kernan; Susan E Prockop; Emily C Zabor; Nicholas Webb; Hugo Castro-Malaspina; Esperanza B Papadopoulos; James W Young; Andromachi Scaradavou; Rachel Kobos; Sergio A Giralt; Richard J O'Reilly; Farid Boulad Journal: Biol Blood Marrow Transplant Date: 2016-05-13 Impact factor: 5.742
Authors: C Michel Zwaan; Edward A Kolb; Dirk Reinhardt; Jonas Abrahamsson; Souichi Adachi; Richard Aplenc; Eveline S J M De Bont; Barbara De Moerloose; Michael Dworzak; Brenda E S Gibson; Henrik Hasle; Guy Leverger; Franco Locatelli; Christine Ragu; Raul C Ribeiro; Carmelo Rizzari; Jeffrey E Rubnitz; Owen P Smith; Lillian Sung; Daisuke Tomizawa; Marry M van den Heuvel-Eibrink; Ursula Creutzig; Gertjan J L Kaspers Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Julia W Cohen; Srivandana Akshintala; Eli Kane; Helen Gnanapragasam; Brigitte C Widemann; Seth M Steinberg; Nirali N Shah Journal: Oncologist Date: 2020-01-14